Login / Signup

Safety and tolerability of subcutaneous trastuzumab and intravenous pertuzumab as adjuvant treatment for HER2 positive breast cancer: a pilot study.

Chi Yan WongRoland LeungGin Wai KwokJosephine TsangBryan LiThomas YauJoanne Wing Yan Chiu
Published in: Postgraduate medical journal (2023)
Combination of SC trastuzumab and intravenous pertuzumab for HER2-positive breast cancer is a safe and well-tolerated option in adjuvant setting.
Keyphrases
  • positive breast cancer
  • epidermal growth factor receptor
  • metastatic breast cancer
  • early stage
  • tyrosine kinase
  • high dose
  • open label
  • clinical trial
  • randomized controlled trial
  • combination therapy
  • smoking cessation